Rationale

The sequencing of the human genome and the recent advances in post-genomics have revolutionised research into human health and diseases. Integrating the vast amounts of data, understanding underlying biological processes and developing key technologies for health-related bio-industries requires the bringing together of critical masses of various expertise and resources that are not available at a national level, with a view to developing knowledge and capacity for intervention. Significant advances in translational health research, which is essential to ensure that biomedical research provides practical benefits and improves life quality, also require multidisciplinary and pan-European approaches involving different stakeholders. Such approaches allow Europe to contribute more effectively to international efforts to combat diseases of global importance. Clinical research on many diseases (e.g. cancer, cardiovascular and infectious diseases, mental and neurological diseases, in particular those linked with ageing, such as Alzheimer and Parkinson diseases) relies on international multi-centre trials to achieve the required number of patients in a short time-frame. Epidemiological research requires a large diversity of populations and international networks to reach significant conclusions. Developing new diagnostics and treatments for rare disorders, as well as performing epidemiological research on those disorders, also requires multi-country approaches to increase the number of patients for each study. In addition, performing health policy-driven research at the European level enables comparisons to be made of the models, systems, data, and patient material held in national databases and biobanks. Strong EU-based biomedical research will help strengthen the competitiveness of the European healthcare biotechnology, medical technology and pharmaceutical industries. EU collaboration with developing countries will allow those countries to develop research capacities. The EU must also play an active role in creating an environment conducive to innovation in public and pharmaceutical sectors which address public health needs, in particular to maximise the success of clinical research. Research-based SMEs are the main economic drivers of the healthcare biotechnology and medical technology industries. Although Europe now has more biotechnology companies than the US, most of them are small and less mature than their competitors. Public-private research efforts at the EU level will facilitate their development. EU research will also contribute to the development of new norms and standards to set up an appropriate legislative framework for new medical technologies (e.g. regenerative medicine). The global leadership of European research and innovation in the field of alternative testing strategies, in particular non-animal methods, should be ensured. The activities that will be addressed, which include research essential to policy requirements, are set out below. Long-term research agendas such as those established by European Technology Platforms, such as the one on innovative medicines, will be supported where relevant. To respond to new policy needs, additional actions may be supported in, for example, the areas of health policy issues and occupational health and safety. The strategic issues of child health and paediatric diseases as well as of the health of the ageing population will receive specific attention and will have to be taken into account whenever appropriate across all activities in this theme. Ethical, legal and socio-economic issues will be taken into account within each of the following activities.

← anx_I__cpt_1__cpt_5__cpt_1__cpt_1__text_1 · All articles · anx_I__cpt_1__cpt_5__cpt_1__cpt_2__text_1 →

Source: EUR-Lex (Cellar) · retrieved 2026-11-04 · Text as adopted (Official Journal); later amendments are not incorporated in this text.